Format

Send to

Choose Destination
Curr Opin Pharmacol. 2017 Jun;34:36-48. doi: 10.1016/j.coph.2017.04.002. Epub 2017 May 6.

Pharmacological advances for treatment in Duchenne muscular dystrophy.

Author information

1
Medical Research Council Functional Genomics Unit at the University of Oxford, Department of Physiology, Anatomy and Genetics, Oxford OX1 3PT, United Kingdom.
2
Medical Research Council Functional Genomics Unit at the University of Oxford, Department of Physiology, Anatomy and Genetics, Oxford OX1 3PT, United Kingdom. Electronic address: kay.davies@dpag.ox.ac.uk.

Abstract

Duchenne muscular dystrophy (DMD) is a lethal, X-linked muscle-wasting disease caused by lack of dystrophin, essential for muscle fibre integrity. Despite extensive pre-clinical studies, development of an effective treatment has proved challenging. More recently, significant progress has been made with the first drug approval using a genetic approach and the application of pharmacological agents which slow the progression of the disease. Drug development for DMD has mainly used two strategies: (1) the restoration of dystrophin expression or the expression of the compensatory utrophin protein as an efficient surrogate, and (2) the mitigation of secondary downstream pathological mechanisms. This review details current most promising pharmacological approaches and clinical trials aiming to tackle the pathogenesis of this multifaceted disorder.

PMID:
28486179
DOI:
10.1016/j.coph.2017.04.002
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center